Pétervári, Mátyás
Benczik, Bettina
Balogh, Olivér M.
Petrovich, Balázs
Ágg, Bence
Ferdinandy, Péter
Funding for this research was provided by:
National Research, Development and Innovation Office of Hungary (NVKP-16-1-2016-0017 National Heart Program)
Ministry for Innovation and Technology (2020-4.1.1.-TKP2020)
Development and Innovation Office of the Ministry of Innovation and Technology (TKP/ITM/NKFIH)
Nemzeti Kutatási, Fejlesztési és Innovaciós Alap (ÚNKP-20-4-I-SE-7, ÚNKP-21-4-II-SE-18)
Emberi Eroforrások Minisztériuma (EFOP-3.6.3-VEKOP-16-2017-00009)
European Union (RRF-2.3.1-21-2022-00003)
Semmelweis University
Article History
Accepted: 7 August 2022
First Online: 6 October 2022
Declarations
:
: Open access funding provided by Semmelweis University. This study was supported by the National Research, Development and Innovation Office of Hungary (NKFIA; NVKP-16-1-2016-0017 National Heart Program). The Ministry for Innovation and Technology in Hungary provided funding to this study under Thematic Excellence Programme (2020-4.1.1.-TKP2020), 2020-1.1.5-GYORSÍTÓSÁV call programme (2020-1.1.5-GYORSÍTÓSÁV-2021-00011), TKP2021-EGA funding scheme (TKP2021-EGA-23), Research Excellence Programme (TKP/ITM/NKFIH). This study was also supported by Project no. RRF-2.3.1-21-2022-00003 implemented with the support provided by the EU. BÁ was supported by the New National Excellence Program of the Ministry for Innovation and Technology from the National Research, Development and Innovation Fund source (ÚNKP-20-4-I-SE-7, ÚNKP-21-4-II-SE-18), and MP was supported by EFOP-3.6.3-VEKOP-16-2017-00009 “Semmelweis 250+ Kiválósági PhD Ösztöndíj” grant.
: PF is the founder and CEO of, and BÁ is employed by, Pharmahungary Group, a group of research and development (R&D) companies (ExternalRef removed) and the provider of Vigilace™. MP is the founder and CEO of Sanovigado Kft, a pharmaceutical consultancy and R&D company. BB, OB, and BP declare they have no conflicts of interest.
: Ethics approval was obtained from the Semmelweis University Regional and Institutional Committee of Science and Research Ethics (SE RKEB 82/2018)
: This study was based on administrative claims data and therefore did not require patient consent.
: Not applicable.
: Unpublished data related to this study are available from the corresponding author on reasonable request.
: The code is the intellectual property of Pharmahungary Group and Semmelweis University.
: MP: Software coding and architecture design; study design; data curation, analysis, and interpretation; drafting of the manuscript. BB: Statistical analysis, data interpretation. OB, BP: Software coding. BÁ: Software architecture, study design, data interpretation, critical revision of the manuscript. PF: Funding acquisition, study design, critical revision of the manuscript. All authors read and approved the final manuscript.